Tyrosine Kinase ETK/BMX Is Up-Regulated in Bladder Cancer and Predicts Poor Prognosis in Patients with Cystectomy

Shengjie Guo1,4, Feng Sun1, Zhiyong Guo1, Wei Li1, Alan Alfano1, Hegang Chen2, Clara E. Magyar5, Jiaoti Huang5, Toby C. Chai3, Shaopeng Qiu4,*, Yun Qiu1*

1 Department of Pharmacology and Experimental Therapeutics and The Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland, United States of America, 2 Department of Epidemiology and Preventive Medicine, University of Maryland School of Medicine, Baltimore, Maryland, United States of America, 3 Division of Urology, University of Maryland School of Medicine, Baltimore, Maryland, United States of America, 4 Department of Urology, First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, 5 Department of Pathology and Laboratory Medicine, The David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, United States of America

Abstract

Deregulation of the non-receptor tyrosine kinase ETK/BMX has been reported in several solid tumors. In this report, we demonstrated that ETK is progressively increased during bladder cancer progression. We found that downregulation of ETK in bladder cancer cells attenuated STAT3 and AKT activity whereas exogenous overexpression of ETK had opposite effects, suggesting that deregulation of ETK may attribute to the elevated activity of STAT3 and AKT frequently detected in bladder cancer. The survival, migration and invasion of bladder cancer cells were significantly compromised when ETK expression was knocked down by a specific shRNA. In addition, we showed that ETK localizes to mitochondria in bladder cancer cells through interacting with Bcl-XL and regulating ROS production and drug sensitivity. Therefore, ETK may play an important role in regulating survival, migration and invasion by modulating multiple signaling pathways in bladder cancer cells. Immunohistochemistry analysis on tissue microarrays containing 619 human bladder tissue samples shows that ETK is significantly upregulated during bladder cancer development and progression and ETK expression level predicts the survival rate of patients with cystectomy. Taken together, our results suggest that ETK may potentially serve as a new drug target for bladder cancer treatment as well as a biomarker which could be used to identify patients with higher mortality risk, who may be benefited from therapeutics targeting ETK activity.

Introduction

Bladder cancer is one of the most common cancers in the United States. It is estimated that there will be 70,530 new cases and 14,680 deaths due to bladder cancer in 2010 [1,2,3]. Multiple genetic and epigenetic factors are believed to contribute to the risk of developing bladder cancer. In addition to well known risk factors such as aging, gender, exposure to cigarette smoke and industrial chemicals, several genetic lesions that provide cues for cell transformation, proliferation, migration and invasion in bladder cancer have been identified [4]. These include mutations or alterations in expression of p53, pRb, E-cadherin, COX2, BLCA-1, CXCL1, MMP-2/9 and EGFR [5]. Cumulative increase in these genetic defects also provides prognostic assessment for disease outcome. However, further understanding of bladder tumor biology is necessary to develop more effective therapy. There is thus a need for the identification and application of novel therapeutic targets in bladder cancer.

Epithelial and endothelial tyrosine kinase (ETK), also known as Bone Marrow X kinase (BMX), is a member of Tec family non-receptor tyrosine kinase. ETK contains an NH2-terminal Pleckstrin homology domain, a Src homology 3 domain, a Src homology 2 domain, and a COOH-terminal tyrosine kinase domain [6]. ETK can be activated by several extracellular stimuli, including growth factors, cytokines, extracellular matrix and hormones [7]. ETK protein is present in cytoplasm with strong perinuclear staining in cells when examined using immunofluorescence microscopy [8,9,10]. Activation of ETK kinase activity can be achieved by interaction of its pleckstrin homology domain either with the phosphatidylinositol 3-kinase product phosphatidylinositol 3,4,5-trisphosphate or the FERM domain of FAK, which leads to plasma membrane translocation of ETK [6,8]. ETK has been shown to play a role in various cellular processes including cell proliferation, transformation, differentiation, migration and metastasis. ETK can interact with FAK and p130Cas to regulate actin cytoskeleton and cell motility [8,11]. It has also been shown that ETK directly interacts with tumor suppress p53 and inhibit its nuclear translocation, thereby promoting chemoresistance in cancer cells [9]. We previously showed that ETK is progressively upregulated during human prostate cancer develop-
ment and progression [12,13]. However, the role of ETK in bladder cancer cells remains unknown.

In this report, we demonstrated that ETK expression is progressively increased during bladder cancer progression. ETK plays an important role in regulating survival, migration and invasion by modulating multiple signaling pathways in bladder cancer cells. We further showed that ETK is also located in mitochondria through directly interacting with Bcl-XL and regulating ROS production in response to treatment of chemotherapeutic drugs. Furthermore, ETK expression positively correlates tumor grade and predicts patient outcome. Our data suggest that ETK may potentially serve as a drug target and prognostic marker for bladder cancer.

**Results**

**Functional Etk is overexpressed in bladder cancer**

We examined ETK expression in a panel of human bladder cancer cell lines and found that ETK expression level was varied in these cells. Interestingly, a significantly higher level of ETK protein was detected in UM-UC-3 and T24 cells which are derived from high-grade and invasive bladder tumors (Fig. 1A). We then examined whether ETK is functional in these invasive cells. We first tested whether growth factor could activate ETK kinase activity using phosphorylation of tyrosine 40 (Y40), an autophosphorylation site by ETK upon its activation [8], as readout. As shown in Fig. 1B, EGF treatment induced Y40 phosphorylation, suggesting that ETK is active in bladder cancer cells. Consistent with previous studies showed that ETK is upstream of STAT3 and AKT pathways [15,16], we found the phosphorylation level of both STAT3 and AKT was compromised when ETK expression was knocked down by a specific shRNA (Fig. 1C, Left). Conversely, when we overexpressed ETK in 5637 cells with a relatively lower level of endogenous ETK, we detected an increased activity of both STAT3 and AKT (Fig. 1C, Right). These data together indicated that ETK is highly expressed in invasive bladder cancer cell lines and involved in regulating STAT3 and AKT activity.

**ETK is present in mitochondria and associated with Bcl-XL**

When we examined cellular localization of ETK in bladder cancer cells, we observed a punctate distribution of ETK in the cytoplasm. Interestingly, ETK staining was partially overlapped with Mitotracker labeling in these cells (Fig. 2A). We also detected a significant amount of ETK protein in the mitochondrial fraction, along with other known mitochondrial proteins Bcl-XL and VDAC (Fig. 2B). As ETK lacks a mitochondria targeting signal, we wondered whether it could localize to mitochondria through a protein-protein interaction. As shown in Fig. 2C, endogenous Bcl-XL was co-precipitated with ETK in both bladder cancer cell lines examined. Similar results were also obtained in 293T cells overexpressing both T7-tagged ETK and GFP-tagged Bcl-XL. These data suggested that ETK may form a complex with Bcl-XL and localize to mitochondria. Due to Bcl-XL’s anti-apoptotic function, we examined the role of ETK in regulating apoptosis in these cells. As shown in Fig. 3A, knock-down of ETK expression by a specific shRNA significantly increased the number of apoptotic cells in UM-UC-3 and T24 cells. In addition, inhibition of ETK activity enhanced ROS production and cytotoxicity in bladder cancer cells in response to treatment of Doxorubicin, while overexpression of ETK had protective effects (Fig. 3B & 3C). Tumor growth and metastasis is regulated in part by the ability of tumor cells to degrade surrounding matrix tissue and migrate. To test whether ETK upregulation may cause such a phenotype, we further examined the effects of ETK knock-down on bladder cancer cell migration and invasion using the Boyden chamber assays. Fig. 3D shows that migration of ETK-knockdown UM-UC-3 and T24 cells was reduced to 40% and 60% respectively compared with the control shRNA treated cells. Similar results were also observed when we examined their ability to invade through matrigel. These data suggested that inhibition of ETK expression in bladder cancer cells compromised both migration and invasion.

**ETK is upregulated in human bladder cancer tissue and predicted patient survival**

To examine ETK expression in human bladder tumor tissues, we performed immunohistochemistry analysis on human bladder
tissue microarrays containing 619 tissue samples from 233 patients. ETK staining appeared to be both cytoplasmic and nuclear positive (Fig. 4A), and ETK expression was markedly increased in bladder tumor tissues compared to their benign counterparts (Table 1). In addition, ETK expression level was significantly higher in invasive T1-T4 tumors than that in non-invasive Tis/Ta counterparts (p < 0.001); however, ETK expression did not differ significantly within T1 to T4 tumors (data not shown). In addition, ETK expression increased with tumor grade (p < 0.001). ETK expression in CIS was a notable exception, with a mean 12% in cytoplasm, which is lower than G1–G3 scores (Table 1), suggesting an association of ETK overexpression with bladder papillary tumors. To assess whether ETK could be used as a potential prognostic marker, clinical outcome analysis was performed on 118 patients underwent cystectomy who were followed up for a median of 92.3 months. We identified a cutoff point of 15% for optimal substratification of these patients according to ETK cytoplasmic expression. There were 75 tumors (64%) with low expression (≤15%) and 43 tumors (36%) with high expression (>15%). Kaplan-Meier analysis indicated that patients who had higher cytoplasmic staining of ETK (staining score >15%) had poorer overall survival probability (Fig. 4B, log-rank test p = 0.0028). Furthermore, multivariable Cox Regression Analysis showed that ETK is a significant predictor of survival after adjusting for other important clinicopathological variables including age, tumor grade, stage and positive lymph node status (Table 2). As indicated in the model, ETK was the only independent prognostic predictor for overall survival with hazard ratio of 1.7 (95% CI: 1.1 to 2.7, p = 0.0159). Taken together, these data showed that ETK expression is increased in bladder cancer and associated with tumor progression and poor prognosis.

**Discussion**

Overexpression of ETK has been reported in several cancers, including prostate, breast and lung cancers [8,13,17,18]. This is the first report on deregulation of ETK expression in bladder cancer. Frequently elevated ETK expression in bladder cancer cells suggested that ETK may play a causal role in disease development and progression. This was supported by our

---

**Figure 2.** ETK localizes to mitochondria and interacts with Bcl-XL in bladder cancer cells. A, ETK localizes to mitochondria in UM-UC-3 and T24 cells. Cells were labeled with Rhodamine Mitotracker, followed by immunofluorescence staining with anti-ETK. Nuclei were counterstained using DAPI. Localization of ETK was determined by confocal microscopy. Yellow shows colocalization of ETK and Mitotracker. B, ETK protein is detected in mitochondrial fraction. Mitochondrial and cytosolic fractions were prepared as described in Methods. The fractionated extracts were subjected to immunoblotting with anti-ETK or indicated antibodies for fractionation markers. ERK was used as a cytosolic marker, while Bcl-XL and VDAC as mitochondrial markers. C, ETK is associated with Bcl-XL. Total cell extracts from UM-UC-3 and T24 cells were immunoprecipitated with anti-ETK or IgG control, followed by immunoblotting with the antibodies as indicated (Left panel). 293T cells were co-transfected with T7-Etk and GFP-Bcl-XL, immunoprecipitation was performed using anti-T7 (Center panel) or anti-GFP (Right panel), followed by immunoblotting with the antibodies as indicated.

doi:10.1371/journal.pone.0017778.g002
Figure 3. Regulation of survival, migration and invasion by ETK in bladder cancer cells. A, Down-regulation of ETK expression induced apoptosis in bladder cancer cells. UM-UC-3 and T24 cells were infected with lentivirus encoding the specific shRNA for ETK for 96 h and apoptosis was evaluated by TUNEL assays. Apoptotic cells were quantified by counting TUNEL-positive cells from five random independent fields. B, ETK regulates ROS activity and cytotoxicity in bladder cancer cells in response to Doxorubicin (DOX) treatment. Cells were infected with lentivirus encoding the shRNA specific for ETK, Etk T7-tagged ETK or a vector control. At 48 h postinfection, cells were treated with DOX (UM-UC-3, 0.5 µg/ml; T24 cells, 2.5 µg/ml) for 20 h and then incubated with 10 nM 5(6)-CDCFDA for 30 min. ROS-positive cells were counted under the fluorescence microscopy. The results were expressed as percentage of the control. C, ETK regulates cytotoxicity in bladder cancer cells in response to DOX treatment. Cells were infected as described in B and treated with DOX (T24, 5 µg/ml; UM-UC-3, 0.5 µg/ml) for 48 h. Cell viability was assessed by WST-1 assays (Top panel). The level of ETK expression was monitored by immunoblotting with anti-ETK (Bottom panel). *, p<0.05 compared with the control; **, p<0.01 compared with the control. D, Knockdown of ETK inhibited migration and invasion in vitro. Cell migration and invasion assay were described as Methods. The results were expressed as percentage of the control. *, p<0.05 compared with the control; **, p<0.01 compared with the control. doi:10.1371/journal.pone.0017778.g003
observation that ETK activity could be stimulated by EGF, which
was previously demonstrated to induce growth and enhance
invasion of bladder cancer cells by regulating AKT activity [19,20].
The EGF receptor has been reported highly expressed in
bladder cancer cells and is associated with cancer progression and
poor prognosis in patients [21,22,23]. Therefore, ETK may likely
act as a downstream effector of EGF/EGFR to promote bladder
tumor growth and metastasis. It has been shown that ETK
overexpression can increase proliferation in mouse prostate
epithelium and result in development of prostatic intraepithelial
neoplasia (PIN) partly by increasing AKT and STAT3 activity
[13]. We found that down-regulation of ETK in bladder cancer
cells attenuated STAT3 and AKT activity whereas exogenous
overexpression of ETK had opposite effects. Deregulation of
STAT3 and PI3K/AKT pathways has been shown to play an
important role in the development of urothelial carcinoma and
correlates with tumor progression [24,25]. It is possible that ETK
may exert its role in bladder cancer through regulating these

Figure 4. A, The representative fields of human bladder cancer TMAs stained with anti-ETK antibody. B, Kaplan-Meier analysis on association of ETK cytoplasmic staining with the survival rate of patients with cystectomy.
doi:10.1371/journal.pone.0017778.g004
ETK Predicts Poor Prognosis in Bladder Cancer

Table 1. ETK cytoplasmic expression in bladder tissue.

| Group              | Mean ± SE | N(%) |
|--------------------|-----------|------|
| Grade              |           |      |
| Normal             | 12.66±0.74| 193(32.60) |
| G1                 | 24.42±1.82| 26(4.39) |
| G2                 | 25.18±1.26| 125(21.12) |
| G3                 | 25.55±0.91| 176(29.73) |
| CIS                | 12.17±1.05| 72(12.16) |
| p Value            | <0.0001   |      |
| Stage              |           |      |
| Normal             | 12.66±0.73| 193(31.2) |
| Non-invasive(T1-T4)| 20.49±0.99| 187(30.2) |
| Invasive(T1-T4)    | 25.06±0.82| 239(38.6) |
| p Value            | <0.0001   |      |

doi:10.1371/journal.pone.0017778.t001

Table 2. Multivariate Cox regression analysis on survival in patients with Cystectomy.

| Covariate                     | HR (95% CI) | p Value |
|-------------------------------|-------------|---------|
| Age≤70 yr                     | 1.512 (0.968–2.361) | 0.0692  |
| Grade 3 vs 1–2                | 1.264 (0.635–2.514) | 0.5045  |
| Stage T1-T4 vs T1-T4          | 1.167 (0.480–2.837) | 0.7325  |
| N+ vs N0                      | 1.650 (0.934–2.913) | 0.0845  |
| Etk Cytoplasmic (>15)         | 1.732 (1.108–2.706) | 0.0159  |

doi:10.1371/journal.pone.0017778.t002

In addition to STAT3 and AKT pathways which are known to be activated by ETK, we also showed, for the first time, that ETK localizes to mitochondria in bladder cancer cells and thereby regulates ROS production and drug sensitivity. Other tyrosine kinases, including Src and EGFR, have been shown to be present in mitochondria. Salvi et al reported that Src is located in mitochondria in rat brain [26]. EGFR and Src can translocate to mitochondria by binding the subunit II of mitochondrial cytochrome oxidase (Cox2) as a result of cell mitosis, and regulate mitochondrial function through phosphorylating Cox2 [27]. However, the exact function of ETK in mitochondria has yet to be established. We found that ETK is associated with a Bcl-2 family member Bcl-XL in bladder cancer cells. Knockdown of ETK expression leads to an increase of ROS production and sensitization of bladder cancer cell to chemotherapeutic drugs. It has been shown that DNA damage, irradiation and hypoxia can induce ROS in cancer cells [28,29]. Therefore, ETK may potentially serve as a new drug target for bladder cancer treatment as well as a biomarker which could be used to stratify patients with higher mortality risk. These patients may be beneficial from therapeutics targeting ETK activity.

Materials and Methods

Cell Culture, transfection and lentiviral infection

Human bladder cancer cell line T24, 5637, J82, RT-4 and UM-UC-3 as well as 293T were purchased from American Type Culture Collection (ATCC). UM-UC-3, T24 and 293T cells were grown in Dulbecco's modified Eagle's medium, 5637, J82 and RT-4 cells were maintained in RPMI 1640 with 10% fetal bovine serum and 1% (v/v) penicillin and streptomycin (100 μg/ml) and maintained at 37°C in a 5% CO2 atmosphere. Cells were transfected with HD FuGENE 6 (Roche Molecular Biochemicals) following the manufacturer's instruction. Lentivirus infection was carried out as previously [9].

Immunoprecipitation and Western Blot

Cells were lysed in the lysis buffer (20 mM Tris/HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 1 mM Na3VO4, 1 mg/ml aprotinin, 1 mg/ml leupeptin, and 1 mM phenylmethyl-sulfonyl fluoride). Insoluble material was removed by centrifugation, and antibodies were added to lysis for overnight at 4°C. Antibodies were collected using protein A or protein G-Sepharose beads, and protein complexes were washed three times at 4°C with the lysis buffer. Immunoblotting was done using the lysis buffer.

Figure 5. Postulated role of ETK in bladder cancer.

doi:10.1371/journal.pone.0017778.g005

Table 2. Multivariate Cox regression analysis on survival in patients with Cystectomy.
as described previously [9]. Briefly, the equal amounts of sample were resolved on a SDS polyacrylamide gel and transferred to a polyvinylidene difluoride membrane. Blots were incubated with the indicated primary antibodies overnight at 4°C and followed by detection with horseradish peroxidase-conjugated secondary antibody. The monoclonal anti-BMX antibody (BD Transduction Laboratories) was used at 1:2000, whereas anti-pSTAT3 (Y705), AKT, pAKT (S473), EGFR, pEGFR (Y1175) and pETK (Y40) (Cell Signaling Technology, Danvers, MA) were used at 1:1,000. Anti-Bcl-2, anti-tubulin, ERK, VDAC and anti-signal transducers and activators of transcription 3 (STAT3) (Santa Cruz Biotechnology, Santa Cruz, CA) were used at 1:2,000.

**WST-1, colony formation and TUNEL assays**

Cells were seeded in 96-well plates at a density of 1 x 10^3 cell/well and infected with the lentivirus encoding the ETK shRNA or a control shRNA. At each indicated time point, cell viability was measured by WST-1 (Roche) assay following the manufacturer’s protocol. For colony formation assay, cells (1 x 10^5) were seeded in 6-well plates and infected with the lentivirus for control shRNA or ETK shRNA. Cell culture was maintained in complete medium for 14 days, and colonies were then visualized by Coomassie blue staining. UM-UC-3 and T24 cells were infected with the lentivirus encoding ETK shRNA or a control for 96 h and apoptotic cells were detected by TUNEL assay following the manufacturer’s instructions (Roche). Apoptotic cells were quantified by counting TUNEL-positive cells from five random independent fields.

**Cell migration and invasion assays**

Cell migration was assessed by transwell assay as described previously [8]. Briefly, infected cells were harvested, resuspended in serum-free medium, and then transferred to the top chambers (5 x 10^4 cells per well) while the bottom chambers containing 0.5 ml of Conditioned medium from NIH 3T3 fibroblasts. After 24 h incubation, cells on the upper surface were scraped and washed away, whereas the cells migrated to the lower surface were fixed and stained with 4',6-diamidino-2-phenylindole (DAPI) for 5 min and then counted under a fluorescence microscope, and the relative number to the vector control was calculated. Cell invasion assay was performed with the MultiStain script. Thresholded analyses were performed with the Ariol analytical software for each image were applied using the Ariol analytical software based on multiple parameters: RGB algorithm, shape and size. All analyses were performed with the MultiStain script. Thresholded classifiers were customized for each stain.

For assessing nuclear staining, positive DAB staining was calculated by applying two color thresholds with one recognizing blue background (haematoxylin stained) cells and another recognizing brown positive cells and blue, non-positive cells (total cell number). Individual cells were discriminated by incorporating the shape and size thresholds, providing, together with the color thresholds, actual cell counts. Percent of positivity was determined by dividing the cell number detected by the brown threshold by the total cell number, detected by the sum of the brown and blue thresholds. Total tissue area analyzed was also included in the final analysis (μm²).

For assessing cytoplasmic staining, the area positive stain was calculated by applying color thresholds with one recognizing blue background (haematoxylin stained) cells and another recognizing brown positive cells and blue, non-positive cells (total cell number). Individual cells were discriminated by incorporating the shape and size thresholds, providing, together with the color thresholds, actual cell counts. Percent of positivity was determined by dividing the cell number detected by the brown threshold by the total cell number, detected by the sum of the brown and blue thresholds. Total tissue area analyzed was also included in the final analysis (μm²).

**Tissue microarray, Immunohistochemistry and Statistical analysis**

Tissue microarrays (TMAs) were prepared by the department of Pathology at the University of California, Los Angeles (UCLA) Medical Center as previously described [14]. Investigators were only provided with clinical-pathological data such as the tumor stage and grade. All patient identifiers were removed so that it is not possible to trace any tissue to a particular patient. Therefore, patient confidentiality is protected. Under the protocol approved by the IRB committee at UCLA, no patient consent is required for this study. TMA were deparaffinized with xylene and stained as previously described [13]. Briefly, slides were rehydrated and antigen retrieval was achieved by microwave for 15 min in citrate buffer. Slides were then incubated in 0.3% hydrogen peroxide to quench endogenous horseradish peroxidase (HRP) for 30 min. Slides were re-incubated with normal goat serum in PBS (1:20) for 60 min at room temperature. Slides were then incubated with primary antibody ETK (1:2000) at 4°C overnight. Subsequently, slides were incubated with biotin-labeled anti-rabbit IgG and incubated with preformed avidin-biotin peroxidase complex. Finally, the slides were counterstained with hematoxylin, dehydrated and mounted.

Slides were analyzed using the Ariol SL-50 automated slide scanner (Applied Imaging, San Jose, Calif) to quantitate the amount of positive staining for each area of interest. Thresholds for each image were applied using the Ariol analytical software based on multiple parameters: RGB algorithm, shape and size. All analyses were performed with the MultiStain script. Thresholded classifiers were customized for each stain.

For assessing nuclear staining, positive DAB staining was calculated by applying two color thresholds with one recognizing blue background (haematoxylin stained) cells and another recognizing brown positive cells and blue, non-positive cells (total cell number). Individual cells were discriminated by incorporating the shape and size thresholds, providing, together with the color thresholds, actual cell counts. Percent of positivity was determined by dividing the cell number detected by the brown threshold by the total cell number, detected by the sum of the brown and blue thresholds. Total tissue area analyzed was also included in the final analysis (μm²).

For assessing cytoplasmic staining, the area positive stain was calculated by applying color thresholds with one recognizing blue background (haematoxylin stained) cells and another recognizing brown positive cells and blue, non-positive cells (total cell number). Individual cells were discriminated by incorporating the shape and size thresholds, providing, together with the color thresholds, actual cell counts. Percent of positivity was determined by dividing the cell number detected by the brown threshold by the total cell number, detected by the sum of the brown and blue thresholds. Total tissue area analyzed was also included in the final analysis (μm²).

**Mitochondrial preparation and Reactive Oxygen Species (ROS) detection**

Mitochondria fraction was purified with Mitochondria Isolation Kit for Cultured Cells (PIERCE) according to the manufacturer’s instructions. Intracellular ROS was measured by using the dye 5(6)-CFDA (molecular probes). After passing through the plasma membrane, this lipophilic and non-fluorescent compound is deestersified to a hydrophilic alcohol (H2DCF) that may be oxidized to fluorescent DCF by a process usually considered to involve with ROS. Cultured cells were loaded with 10 μM 5(6)-CFDA in normal medium at 37°C for 30 min. After incubation, cells were washed three times with medium and left the last washing medium for imaging studies. Imaging was taken by fluorescence microscope using a Nikon TE2000s inverted microscope with 10x objective.
COX multiple proportional hazards model was used to assess which covariates affect survival/recurrence-free time. For each covariate, the relative hazard rate and the associated P-value were reported. All analyses were performed with the software SAS version 9.2.

Acknowledgments

We would like to thank Dr. Allan J. Pantuck for his advice on data analysis.

References

1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277–300.
2. Edwards BK, Ward E, Kohler BA, Ederer F, Stovall M, et al. (2010) Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future cancer. Cancer 116: 544–573.
3. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer Statistics, 2010. CA Cancer J Clin.
4. Hartge P, Harvey EB, Linehan WM, Silverman DT, Sullivan JW, et al. (1990) Unexplained excess risk of bladder cancer in men. J Natl Cancer Inst 82: 1636–1640.
5. Jacobs BL, Lee CT, Montie JE (2010) Bladder cancer in 2010: how far have we come? CA Cancer J Clin 60: 244–272.
6. Qiu Y, Robinson D, Perillow TG, Kung HJ (1998) Etk/Bmx, a tyrosine kinase and a pleckstrin-homology domain-containing protein, is an effector of phosphatidylinositol 3'-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells. Proc Natl Acad Sci U S A 95: 3644–3649.
7. Qiu Y, Kung HJ (2000) Signaling network of the Btk family kinases. Oncogene 19: 5651–5661.
8. Chen R, Kim O, Li M, Xiong X, Guan JL, et al. (2001) Regulation of the PH-domain-containing tyrosine kinase Etk by focal adhesion kinase through the FERM domain. Nat Cell Biol 3: 439–444.
9. Jiang T, Guo Z, Dai B, Kang M, Ann DK, et al. (2004) Bidirectional regulation between tyrosine kinase Etk/BMX and tumor suppressor p53 in response to DNA damage. J Biol Chem 279: 50181–50189.
10. Yang J, Kim O, Wu J, Qiu Y (2002) Interaction between tyrosine kinase Etk and a RUN domain-containing protein RUFY1. A possible role of ETK in regulation of vesicle trafficking. J Biol Chem 277: 30219–30226.
11. Abassi YA, Rehm M, Ekmans N, Alitalo K, Vuori K (2003) p130Cas Couples the tyrosine kinase, mediates cellular transformation by linking Src to STAT3 and quantification of the epidermal growth factor receptor in response to androgen deprivation promotes castration-resistant growth of prostate cancer cells. Cancer Res 63: 5307–5316.
12. Dai B, Chen H, Guo S, Yang X, Linn DE, et al. (2010) Compensatory upregulation of tyrosine kinase Etk/BMX in response to androgen deprivation promotes castration-resistant growth of prostate cancer cells. Cancer Res 70: 2507–2516.
13. Dai B, Kim O, Xie Y, Guo Z, Xu K, et al. (2006) Tyrosine kinase Etk/BMX is up-regulated in human prostate cancer and its overexpression induces prostate intraepithelial neoplasia in mouse. Cancer Res 66: 8058–8064.
14. Klatt T, Seligson DH, Rao JY, Yu H, de Marinho M, et al. (2009) Carboxy anhydrase IX in bladder cancer: a diagnostic, prognostic, and therapeutic molecular marker. Cancer 115: 1448–1458.
15. Tsa T, Yu Y, Fang SS, Huang TN, Qiu Y, et al. (2008) Etk, a Btk family tyrosine kinase, mediates cellular transformation by linking Src to STAT3 activation. Mol Cell Biol 20: 2043–2054.
16. Chau CH, Clavijo CA, Deng HT, Zhang Q, Kim KJ, et al. (2005) Etk/Bmx mediates expression of stress-induced adaptive genes VEGF, PAI-1, and iNOS via multiple signaling cascades in different cell systems. Am J Physiol Cell Physiol 289: C444–454.
17. Wen X, Lin HH, Shih HM, Kung HJ, Ann DK (1999) Kinase activation of the non-receptor tyrosine kinase Etk/BMX alone is sufficient to transactivate STAT-mediated gene expression in salivary and lung epithelial cells. J Biol Chem 274: 38204–38210.
18. Chon KY, Huang LM, Kung HJ, Ann DK, Shih HM (2004) The role of tyrosine kinase Etk/Bmx in EGF-induced apoptosis of MDA-MB-468 breast cancer cells. Oncogene 23: 1835–1842.
19. Kuranami M, Yamauchi K, Fuchigami M, Imahashi K, Watanabe T, et al. (1991) Effect of urine on clonal growth of human bladder cancer cell lines. Cancer Res 51: 4631–4635.
20. Chiang GJ, Billmeyer BR, Canes D, Stoffel J, Moinzadeh A, et al. (2005) The src-family kinase inhibitor PP2 suppresses the in vitro invasive phenotype of bladder carcinoma cells via modulation of Akt. BJU Int 96: 416–422.
21. Smith K, Fennelly JA, Neal DE, Hall RR, Harris AL (1989) Characterization and quantification of the epidermal growth factor receptor in invasive and superficial bladder tumors. Cancer Res 49: 5810–5815.
22. Ishikawa J, Maeda S, Sugiyama T, Nishimura R, Muzoguchi A, et al. (1989) EGF stimulates anchorage-independent growth of a human bladder carcinoma cell line (KU1) with an amplified and over-expressed EGF receptor gene. Int J Cancer 44: 1000–1004.
23. Neal DE, Sharples L, Smith K, Fennelly JA, Hall RR, et al. (1990) The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer 65: 1619–1625.
24. Chen CL, Lin CH, Kohout J, Hutaen B, Chan C, et al. (2008) Signal transducer and activator of transcription 3 activation is associated with bladder cancer cell growth and survival. Mol Cancer 7: 78.
25. Itoh M, Murata T, Suzuki T, Shindoh M, Nakajima K, et al. (2006) Requirement of STAT3 activation for maximal collagenase-1 (MMP-1) induction by epidermal growth factor and malignant characteristics in T24 bladder cancer cells. Oncogene 25: 1195–1204.
26. Salvi M, Bruniati AM, Bordin L, La Rocca N, Clari G, et al. (2002) Characterization and location of Src-dependent tyrosine phosphorylation in rat brain mitochondria. Biochim Biophys Acta 1589: 181–193.
27. Dernoy ML, Boerner JL, Davidson R, Faust W, Mizake T, et al. (2009) Epidermal growth factor receptor translocation to the mitochondria: regulation and effect. J Biol Chem 284: 36592–36604.
28. Lee I, Park C, Kang WK (2010) Knockdown of Inwardly Rectifying Potassium Channel Kir2.2 Suppresses Tumorigenesis by Inducing ROS-Mediated Cellular Senescence. Mol Cancer Ther.
29. Moskoff S, Basu JM, Majumder S, Chatterjee S, Panda GS, et al. (2006) A novel copper complex induces ROS generation in doxorubicin resistant Ehrlich ascites carcinoma cells and increases activity of antioxidant enzymes in vital organs in vivo. BMC Cancer 6: 267.
30. Huang WT, Yang SF, Wu CC, Chen WT, Huang YC, et al. (2009) Expression of signal transducer and activator of transcription 3 and suppressor of cytokine signaling 3 in urothelial carcinoma. Kaohsiung J Med Sci 25: 640–646.
31. Mitra AP, Pagliarulo V, Yang D, Waldman FM, Datar RH, et al. (2009) Generation of a concise gene panel for outcome prediction in urinary bladder cancer. J Clin Oncol 27: 3929–3937.

Author Contributions

Conceived and designed the experiments: SG FS YQ. Performed the experiments: SG ZG WL AA. Analyzed the data: CEM JH HC. Contributed reagents/materials/analysis tools: TCC SQ. Wrote the paper: SG CEM JH YQ.

ETK Predicts Poor Prognosis in Bladder Cancer